MX2020013684A - Formulaciones/composiciones que comprenden ibrutinib. - Google Patents

Formulaciones/composiciones que comprenden ibrutinib.

Info

Publication number
MX2020013684A
MX2020013684A MX2020013684A MX2020013684A MX2020013684A MX 2020013684 A MX2020013684 A MX 2020013684A MX 2020013684 A MX2020013684 A MX 2020013684A MX 2020013684 A MX2020013684 A MX 2020013684A MX 2020013684 A MX2020013684 A MX 2020013684A
Authority
MX
Mexico
Prior art keywords
formulations
compositions
ibrutinib
disease
preparing
Prior art date
Application number
MX2020013684A
Other languages
English (en)
Inventor
René Holm
Maristella Bernini
Wenyu Dong
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2020013684A publication Critical patent/MX2020013684A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se divulgan formulaciones/composiciones que comprenden ibrutinib: (ver Fórmula) así como los procesos para preparar dichas formulaciones/composiciones y métodos para el tratamiento de una enfermedad o afección que comprende el uso de dichas formulaciones/composiciones.
MX2020013684A 2018-06-15 2019-06-14 Formulaciones/composiciones que comprenden ibrutinib. MX2020013684A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18177987 2018-06-15
PCT/EP2019/065637 WO2019238904A1 (en) 2018-06-15 2019-06-14 Formulations/compositions comprising ibrutinib

Publications (1)

Publication Number Publication Date
MX2020013684A true MX2020013684A (es) 2021-03-02

Family

ID=62684687

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013684A MX2020013684A (es) 2018-06-15 2019-06-14 Formulaciones/composiciones que comprenden ibrutinib.

Country Status (13)

Country Link
US (1) US20190381174A1 (es)
EP (1) EP3806824A1 (es)
JP (2) JP2021527097A (es)
KR (1) KR20210021348A (es)
CN (1) CN112292117A (es)
AU (1) AU2019287282A1 (es)
BR (1) BR112020024481A2 (es)
CA (1) CA3100146A1 (es)
EA (1) EA202190045A1 (es)
MA (1) MA52874A (es)
MX (1) MX2020013684A (es)
SG (1) SG11202012165WA (es)
WO (1) WO2019238904A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2755094C1 (ru) * 2020-11-12 2021-09-13 Общество С Ограниченной Ответственностью "Научно-Производственная Компания "Фармасофт" Лекарственная форма для инъекций в виде раствора и стабилизатор для его приготовления

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
ATE404206T1 (de) * 2004-12-06 2008-08-15 Janssen Pharmaceutica Nv Orale suspension mit meloxicam
KR101315610B1 (ko) 2006-09-22 2013-10-10 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제 억제제
CN110354132A (zh) 2012-06-04 2019-10-22 药品循环有限责任公司 布鲁顿酪氨酸激酶抑制剂的晶形
WO2014004707A1 (en) 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprising ibrutinib
MX2016005283A (es) * 2013-10-25 2017-02-20 Pharmacyclics Llc Tratamiento que utiliza inhibidores de tirosina quinasa de bruton e inmunoterapia.
WO2015084892A1 (en) * 2013-12-02 2015-06-11 Cornell University Methods for treating b cell proliferative disorders
WO2015187848A1 (en) * 2014-06-04 2015-12-10 Sampath Deepa Hdac inhibitor and btk inhibitor combinations
EP3185870A4 (en) * 2014-08-01 2018-06-20 Pharmacyclics LLC Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
CN106573002A (zh) 2014-08-07 2017-04-19 药品循环有限责任公司 布鲁顿氏酪氨酸激酶抑制剂的新型制剂
TW202315634A (zh) 2015-03-03 2023-04-16 美商製藥公司 布魯東氏（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶抑制劑之醫藥調配物
MA41828A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
US10377758B2 (en) 2015-04-02 2019-08-13 Ratiopharm Gmbh Co-crystals of ibrutinib with carboxylic acids
SG11201707989PA (en) * 2015-04-06 2017-10-30 Janssen Pharmaceutica Nv Compositions containing ibrutinib
CA3008338A1 (en) 2016-01-19 2017-07-27 Janssen Pharmaceutica Nv Formulations/compositions comprising a btk inhibitor
AU2017208473B2 (en) 2016-01-19 2022-04-21 Janssen Pharmaceutica Nv Formulations/compositions comprising a BTK inhibitor
SG11201810333UA (en) * 2016-05-27 2018-12-28 Tg Therapeutics Inc Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders

Also Published As

Publication number Publication date
BR112020024481A2 (pt) 2021-03-02
KR20210021348A (ko) 2021-02-25
MA52874A (fr) 2021-04-21
SG11202012165WA (en) 2021-01-28
WO2019238904A1 (en) 2019-12-19
US20190381174A1 (en) 2019-12-19
EP3806824A1 (en) 2021-04-21
CA3100146A1 (en) 2019-12-19
CN112292117A (zh) 2021-01-29
EA202190045A1 (ru) 2021-03-17
JP2024023262A (ja) 2024-02-21
AU2019287282A1 (en) 2020-11-26
JP2021527097A (ja) 2021-10-11

Similar Documents

Publication Publication Date Title
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
MX2018011114A (es) Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías.
MX2022006768A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MY197631A (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
IL285782A (en) Compounds, compositions, and methods for treating disease
NZ757081A (en) Somatostatin modulators and uses thereof
PH12019502646A1 (en) Pyrazole magl inhibitors
MX2022001310A (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2020001404A (es) Dihidrooxadiazinonas.
GEP20247585B (en) Furoindazole derivatives
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
IL270927B (en) fused 5,6 bicyclic compounds and compounds for the treatment of parasitic diseases
ZA202106519B (en) Caspase inhibitors and methods of use thereof
MX2019007041A (es) Metodos y composiciones para tratar la enfermedad de parkinson.
MX2020013684A (es) Formulaciones/composiciones que comprenden ibrutinib.
MX2017013879A (es) Composiciones que comprenden anakinra.